AstraZeneca

About Us

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca.

Contacts

AstraZeneca
Karlebyhus, Astraallén 151 85 SÖDERTÄLJE
08-553 260 00
08-553 290 00
http://www.astrazeneca.se
kontakt@astrazeneca.com

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

ASTRAZENECA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE PHASE III PROGRAMME OF CAZ-AVI IN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS (cIAI)

Tue, Aug 19, 2014 08:02 CET

CAZ-AVI treated patients with cIAI as effectively as meropenem CAZ-AVI also treated cIAI patients infected with ceftazidime-resistant bacteria as effectively as meropenemAstraZeneca today announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections. CAZ-AVI consists of a cephalosporin (ceftazidime), an established treatment for serious bacterial infections, and a next generation non-

ASTRAZENECA’S NOVEL ANTIBIOTIC CANDIDATE AZD0914 GIVEN FAST TRACK STATUS BY US FDA

Tue, Jun 03, 2014 08:03 CET

AstraZeneca today announced that the US Food and Drug Administration (FDA) has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product (QIDP) and awarded its development programme Fast Track status for the treatment of uncomplicated gonorrhoea, which is increasingly resistant to existing antibiotics and poses a serious global public health threat. AZD0914 is a novel oral antibiotic entering Phase II clinical trials to investigate efficacy in treating uncomplicated gonorrhoea and is the first of a novel class of molecules to be developed for this

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Contacts

ASTRAZENECA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE PHASE III PROGRAMME OF CAZ-AVI IN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS (cIAI)

ASTRAZENECA’S NOVEL ANTIBIOTIC CANDIDATE AZD0914 GIVEN FAST TRACK STATUS BY US FDA

Subscribe